UBS maintained a Buy rating on Actavis (NYSE: ACT) and raised its price target to $254.00 (from $237.00). The change ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE